Eosinophilic Esophagitis

News that the FDA approved Ibsrela to treat irritable bowel syndrome with constipation in adults and the American Society for Gastrointestinal Endoscopy’s updates to its guidelines for screening and surveillance of Barrett’s esophagus were among the top stories in gastroenterology last week.

Researchers from Nemours Children’s Health System identified gene variants that influence the efficacy of proton pump inhibitor therapy in children with eosinophilic esophagitis and said their findings could lead to new opportunities for personalized medicine.

Even after initial histologic response to induction therapy, eosinophilic esophagitis recurs rapidly in patients who discontinue treatment, regardless of the type of medication used, according to results of a randomized controlled trial.